What Is GLP-1? How the Hormone & the Medications Work for Weight Loss (2026)

GLP-1 (glucagon-like peptide-1) is a natural hormone your own gut makes after you eat. It is an "incretin" — released by L-cells in your intestine — and it does four useful things: it tells your pancreas to release insulin when blood sugar is high, it slows how fast your stomach empties so you feel full longer, it acts on the appetite centers in your brain to reduce hunger and quiet "food noise," and it suppresses glucagon (the hormone that raises blood sugar).^[3][4] Your own GLP-1 is short-lived — broken down within minutes by an enzyme called DPP-4. The blockbuster medications people mean when they say "GLP-1" — Ozempic, Wegovy, Mounjaro, Zepbound — are GLP-1 receptor agonists: synthetic drugs that mimic the natural hormone but are engineered to last much longer, so most are taken just once a week.^[1] This guide explains the hormone, the medication class, how well they work, who they are for, and how the appetite and "food noise" effect drives the weight loss. It is general information, not medical advice.

What is GLP-1, the hormone?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body produces naturally — specifically by specialized cells called L-cells that line your small and large intestine. When you eat, those L-cells sense the arriving nutrients and release GLP-1 into the bloodstream. Because it is released in response to food and helps control the rise in blood sugar that follows a meal, GLP-1 belongs to a family of hormones called incretins.^[3][4] It is, in other words, part of your body's normal, everyday system for handling a meal — not something foreign.

Natural GLP-1 does four main jobs:

• Triggers insulin (the incretin effect). GLP-1 tells the pancreas to release insulin — but in a glucose-dependent way, meaning it mainly stimulates insulin when blood sugar is high and backs off when it is normal. That glucose-dependence is why GLP-1 itself rarely causes low blood sugar on its own.^[3][4]
• Slows gastric emptying. GLP-1 slows the rate at which food leaves your stomach, so a meal sits longer and you feel full sooner and for longer. This slowed emptying is also why nausea is the most common side effect of the medications that mimic it.^[4]
• Reduces appetite in the brain. GLP-1 receptors are present in appetite-regulating centers of the brain (including the hypothalamus and brainstem), and GLP-1 acts there to reduce hunger and food intake — the central effect that drives much of the weight loss.^[3]
• Suppresses glucagon. GLP-1 lowers the secretion of glucagon, the pancreatic hormone that raises blood sugar by releasing stored glucose from the liver. Less glucagon means less sugar pushed into the blood after a meal.^[4]

There is one catch that explains the entire drug class: your own GLP-1 is extremely short-lived. Once released, it is degraded within a couple of minutes by an enzyme called DPP-4 (dipeptidyl peptidase-4).^[3][4] That rapid breakdown is great for tight, meal-by-meal control, but it means natural GLP-1 cannot, by itself, produce a sustained appetite-suppressing effect across the day. Solving that — building a GLP-1 molecule that resists DPP-4 and lasts for days — is exactly what the medications do.

What are the GLP-1 medications?

The medications people call "GLP-1s" are formally GLP-1 receptor agonists (sometimes GLP-1 RAs). An "agonist" is a drug that binds to a receptor and activates it the way the natural hormone would. So a GLP-1 receptor agonist switches on the same GLP-1 receptors your own hormone uses — same insulin-stimulating, gut-slowing, appetite-suppressing effects — but the molecule is engineered to resist DPP-4 breakdown and last far longer. Instead of vanishing in minutes, modern agents persist for days, which is why most are injected just once a week.^[1][4]

Here is the class, from the most familiar names to the newest:

• Semaglutide — sold as Ozempic (for type 2 diabetes), Wegovy (for chronic weight management), and Rybelsus (an oral daily tablet). All three are the same molecule, semaglutide; the difference is the brand, the approved use, and the form. Semaglutide produced roughly 15% average body-weight loss in the STEP-1 weight-management trial.^[1][5]
• Tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (weight management). Tirzepatide is a dual GIP/GLP-1 agonist: it activates a second incretin receptor (GIP) in addition to GLP-1, and it is the most potent of the currently approved options for weight loss — about 20%+ average body-weight loss at the top dose in SURMOUNT-1.^[2]
• Liraglutide — sold as Saxenda (weight management) and Victoza (type 2 diabetes). An older GLP-1 agonist that is taken as a daily injection rather than weekly.
• Dulaglutide — sold as Trulicity, a once-weekly GLP-1 agonist used mainly for type 2 diabetes.
• Orforglipron — sold as Foundayo, the newest entrant and the first oral, non-peptide (small-molecule) GLP-1 agonist. Because it is a small molecule rather than a peptide, it survives the gut without the strict fasting-window protocol that oral semaglutide (Rybelsus) requires.
• Retatrutide — an investigational triple agonist (GLP-1 + GIP + glucagon receptors). It is still in clinical trials and not yet FDA-approved, but it is the most-watched next-generation candidate for even larger weight loss.

One more distinction matters in 2026: brand vs. compounded. The names above are the FDA-approved, brand-name products. During the GLP-1 shortages of 2023–2024, telehealth companies also dispensed compounded semaglutide and tirzepatide — pharmacy-made versions of the same active ingredient. As the shortages resolved, the regulatory status of broad commercial compounding tightened. For a fuller picture of the choices, see our guide to oral vs. injectable GLP-1.

The GLP-1 drug class at a glance

How well do GLP-1 medications work for weight loss?

Far better than diet and exercise alone — and that is the reason the class reshaped obesity medicine. The two benchmark trials:

• Semaglutide (Wegovy 2.4 mg) — about 15%. In the pivotal STEP-1 trial, once-weekly semaglutide produced a mean body-weight reduction of roughly 15% over 68 weeks in adults with overweight or obesity, versus about 2.4% with placebo.^[1]
• Tirzepatide (Zepbound 15 mg) — about 20%+. In the pivotal SURMOUNT-1 trial, once-weekly tirzepatide produced mean body-weight reductions of roughly 15% to 21% across its dose tiers over 72 weeks, with the top 15 mg dose at about 21%, versus about 3% with placebo.^[2]

To put those numbers in perspective: lifestyle programs alone typically yield single-digit percentage weight loss that is hard to sustain. A 15–20% reduction is in the range that used to require bariatric surgery to approach. That is why GLP-1 receptor agonists are now first-line pharmacotherapy for obesity. For a direct comparison of the two leaders, see tirzepatide vs. semaglutide head-to-head.

Why they work: the “food noise” effect

Ask people what changed on a GLP-1 and many describe the same thing: the constant background chatter about food — the snacking urges, the second helpings, the 3 p.m. vending-machine pull — simply quiets down. That phenomenon has a name now: "food noise." It is not just willpower returning; it reflects GLP-1 acting on the appetite and reward centers of the brain, reducing both physiological hunger and the cognitive preoccupation with eating.^[3] Combined with slowed gastric emptying — feeling full sooner and longer — the result is that people eat less without the white-knuckle effort that derails most diets. We cover the brain science in depth in GLP-1 and food noise: the neuroscience evidence.

Who are GLP-1 medications for?

Two broad groups, sometimes overlapping:

• Chronic weight management. The weight-loss indications (Wegovy, Zepbound, Saxenda) are generally for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.^[5]
• Type 2 diabetes. The diabetes-indicated products (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus) are used to improve blood-sugar control, often with cardiovascular and weight benefits as well.^[5]

All of these are prescription medications — there is no legitimate over-the-counter GLP-1. You obtain them through a clinician, either in person or via a telehealth provider, and they can be dispensed as the brand-name product or, where applicable, through a compounding channel. Some people are not candidates: there are specific contraindications (for example, a personal or family history of medullary thyroid carcinoma or MEN 2). See who shouldn't take semaglutide for the disqualifiers. If you are evaluating where to start, our editors maintain a ranked list of the best semaglutide providers.

Side effects in brief

The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — which flow directly from the slowed gastric emptying and tend to be worst in the first weeks and just after each dose increase, then ease as the body adapts.^[6] Because GLP-1 stimulates insulin in a glucose-dependent way, the drugs rarely cause low blood sugar on their own, but the risk rises when combined with insulin or a sulfonylurea.^[6] The class also carries a boxed warning regarding thyroid C-cell tumors, based on rodent studies, which is why a personal or family history of medullary thyroid cancer or MEN 2 is a contraindication.^[5] This is a brief overview only — for the full profile, including the serious-but-rare risks (pancreatitis, gallbladder problems), talk to your prescriber and review the prescribing information.

Vetted GLP-1 telehealth providers

If you have decided to explore a GLP-1 prescription, the providers below are vetted by our editors for legitimate prescribing, licensed pharmacies, and clinician oversight. A real provider takes a medical history, titrates you on the label schedule, and follows up on side effects.

Frequently asked questions